

## Principal Investigator Appointed to lead Emyria's MDMA trial

### Highlights:

- Consultant Psychiatrist Dr. Eli Kotler has been appointed Principal Investigator for Emyria's MDMA-assisted psychotherapy trial for Post-Traumatic Stress Disorder (PTSD) developed in partnership with Mind Medicine Australia

---

- The open-label trial involving MDMA-assisted psychotherapy (named "EMDMA-001") will involve the use of MDMA and specially trained therapists to support patients with difficult-to-treat PTSD in a fit-for-purpose facility

---

- Dr. Kotler is an experienced consultant psychiatrist specialising in trauma and addictions and has extensive research experience as Principal and Co-Investigator (Alfred Health) with novel neuropsychiatric therapeutics

---

- As Principal Investigator, Dr. Kotler will assume responsibility for the conduct and delivery of the EMDMA-001 clinical trial which is anticipated to start in Q3, 2021

---

- Emyria intends to develop other, scalable psychedelic-assisted services with Mind Medicine Australia and is scoping opportunities to licence and evaluate novel compounds utilising Emyria's unique data-backed care delivery and drug development model

**Emyria Limited (ASX: EMD)** (Emyria or the Company), a clinical drug development and care delivery company, is pleased to announce the appointment of Consultant Psychiatrist Dr. Eli Kotler as Principal Investigator for its upcoming clinical trial on MDMA-assisted psychotherapy for treatment-resistant Post Traumatic Stress Disorder (PTSD), known as **EMDMA-001** (for a detailed overview see ASX release 05 May 2021).

The appointment compliments Emyria's growing team of Consultant Psychiatrist advisors such as retired Naval Veteran and Consultant Psychiatrist, Dr. Richard Magtengaard (See ASX release 01 Feb 2021).

Furthermore, the appointment builds Emyria's clinical experience in psychedelic-assisted therapies as it seeks to develop evidence-based and scalable clinical services for patients with major mental health concerns in partnership with Mind Medicine Australia (see ASX release 19 NOV 20).

# emyria

## Dr. Kotler's relevant clinical experience in psychedelic-assisted psychotherapy

Dr. Kotler is a Consultant Psychiatrist specialising in trauma and addictions who brings a wealth of relevant clinical experience with novel neuropsychiatric therapeutics:

- Medical Director Malvern Private Hospital
- Founding member Melbourne Neuropsychoanalytic Group
- Independent Medical Expert for Medical Panels, Victoria.
- Adjunct lecturer at Monash Alfred Psychiatry Research Centre.
- Regular speaker at trauma and addiction conferences.
- Advisory committee for annual national addiction conference.
- Leading Australian educator in psychedelics.
- Director at Mind Medicine Australia.
- Completed Certificate in Psychedelic-Assisted Therapies (CPAT).
- Teaching faculty on current CPAT course.



**Emyria's Managing Director, Dr. Michael Winlo**, said: "We're delighted that Dr. Eli Kotler will be working with our clinical team as Principal Investigator on this pivotal trial.

*MDMA-assisted therapy has shown great promise for difficult to treat Post Traumatic Stress Disorder patients. However, these treatments are resource intensive requiring fit-for-purpose facilities as well as specially-trained psychotherapists and clinicians.*

*Along with our partner Mind Medicine Australia, Emyria has been working on building both the clinical delivery and data capture infrastructure required to support and improve these treatments so they can become safe, accredited, cost-effective, accessible and evidence-based options for those patients who need them most.*

*We hope this will be the first of many, pivotal clinical studies helping evaluate the safety and efficacy of known and novel psychedelic-assisted therapies targeting a range of major mental health concerns."*

The terms of Dr. Kotler's appointment are not commercial.

This announcement has been approved and authorised for release by the Managing Director of Emyria Limited.

For further information:

**Dr Michael Winlo**  
**Managing Director**  
**(08) 6559 2800**  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Lexi O'Halloran**  
**Media/Investor Relations**  
**+ 61 (0) 404 577 076**  
[lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)

**Andrew Williams**  
**Media Relations**  
**+61 (0) 412 614 125**  
[andreww@profilemedia.com.au](mailto:andreww@profilemedia.com.au)

# emyria

## About Emyria ([www.emyria.com](http://www.emyria.com))

Emyria Limited is a clinical drug development and care delivery company. **Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - [www.emeraldclinics.com.au](http://www.emeraldclinics.com.au))

**Emyria Data** provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

---

## References:

For more on the latest research in MDMA-assisted therapy please see:

### **MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study**

<https://www.nature.com/articles/s41591-021-01336-3>

*Published 10th May 2021*

---

## Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.